255 related articles for article (PubMed ID: 27387412)
1. Alphavirus protease inhibitors from natural sources: A homology modeling and molecular docking investigation.
Byler KG; Collins JT; Ogungbe IV; Setzer WN
Comput Biol Chem; 2016 Oct; 64():163-184. PubMed ID: 27387412
[TBL] [Abstract][Full Text] [Related]
2. Complete sequence of the genomic RNA of O'nyong-nyong virus and its use in the construction of alphavirus phylogenetic trees.
Levinson RS; Strauss JH; Strauss EG
Virology; 1990 Mar; 175(1):110-23. PubMed ID: 2155505
[TBL] [Abstract][Full Text] [Related]
3. The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff.
Garmashova N; Gorchakov R; Volkova E; Paessler S; Frolova E; Frolov I
J Virol; 2007 Mar; 81(5):2472-84. PubMed ID: 17108023
[TBL] [Abstract][Full Text] [Related]
4. Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses.
Rico AB; Phillips AT; Schountz T; Jarvis DL; Tjalkens RB; Powers AM; Olson KE
Virology; 2016 Dec; 499():30-39. PubMed ID: 27632563
[TBL] [Abstract][Full Text] [Related]
5. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.
Reed DS; Glass PJ; Bakken RR; Barth JF; Lind CM; da Silva L; Hart MK; Rayner J; Alterson K; Custer M; Dudek J; Owens G; Kamrud KI; Parker MD; Smith J
J Virol; 2014 Oct; 88(20):12077-86. PubMed ID: 25122801
[TBL] [Abstract][Full Text] [Related]
6. Validation of a cell-based ELISA as a screening tool identifying anti-alphavirus small-molecule inhibitors.
Spurgers KB; Hurt CR; Cohen JW; Eccelston LT; Lind CM; Lingappa VR; Glass PJ
J Virol Methods; 2013 Oct; 193(1):226-31. PubMed ID: 23764417
[TBL] [Abstract][Full Text] [Related]
7. A Tale of 20 Alphaviruses; Inter-species Diversity and Conserved Interactions Between Viral Non-structural Protein 3 and Stress Granule Proteins.
Nowee G; Bakker JW; Geertsema C; Ros VID; Göertz GP; Fros JJ; Pijlman GP
Front Cell Dev Biol; 2021; 9():625711. PubMed ID: 33644063
[TBL] [Abstract][Full Text] [Related]
8. Vaccine Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses.
Stromberg ZR; Fischer W; Bradfute SB; Kubicek-Sutherland JZ; Hraber P
Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32503232
[TBL] [Abstract][Full Text] [Related]
9. Virus-specific thermostability and heat inactivation profiles of alphaviruses.
Park SL; Huang YJ; Hsu WW; Hettenbach SM; Higgs S; Vanlandingham DL
J Virol Methods; 2016 Aug; 234():152-5. PubMed ID: 27079828
[TBL] [Abstract][Full Text] [Related]
10. Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses.
Lundberg L; Brahms A; Hooper I; Carey B; Lin SC; Dahal B; Narayanan A; Kehn-Hall K
Antiviral Res; 2018 Sep; 157():57-67. PubMed ID: 29981794
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the nucleotide sequences of eastern and western equine encephalomyelitis viruses with those of other alphaviruses and related RNA viruses.
Weaver SC; Hagenbaugh A; Bellew LA; Netesov SV; Volchkov VE; Chang GJ; Clarke DK; Gousset L; Scott TW; Trent DW
Virology; 1993 Nov; 197(1):375-90. PubMed ID: 8105605
[TBL] [Abstract][Full Text] [Related]
12. Specificity Studies of the Venezuelan Equine Encephalitis Virus Non-Structural Protein 2 Protease Using Recombinant Fluorescent Substrates.
Bozóki B; Mótyán JA; Hoffka G; Waugh DS; Tőzsér J
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081394
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
Fierro C; Weidenthaler H; Vidojkovic S; Schmidt D; Gafoor Z; Stroukova D; Zwiers S; Müller J; Volkmann A
Vaccine; 2024 Apr; 42(10):2695-2706. PubMed ID: 38494412
[TBL] [Abstract][Full Text] [Related]
14. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas.
Reichert E; Clase A; Bacetty A; Larsen J
Biosecur Bioterror; 2009 Dec; 7(4):413-27. PubMed ID: 20028250
[TBL] [Abstract][Full Text] [Related]
15. Identification of Quinolinones as Antivirals against Venezuelan Equine Encephalitis Virus.
Haese NN; May NA; Taft-Benz S; Moukha-Chafiq O; Madadi N; Zhang S; Karyakarte SD; Rodzinak KJ; Nguyen TH; Denton M; Streblow AD; Towers NA; Rasmussen L; Bostwick RJ; Maddry JA; Ananthan S; Augelli-Szafran CE; Suto MJ; Sanders W; Moorman N; DeFilippis V; Heise MT; Pathak AK; Streblow DN; Morrison TE
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0024421. PubMed ID: 34152810
[TBL] [Abstract][Full Text] [Related]
16. Host translation shutoff mediated by non-structural protein 2 is a critical factor in the antiviral state resistance of Venezuelan equine encephalitis virus.
Bhalla N; Sun C; Metthew Lam LK; Gardner CL; Ryman KD; Klimstra WB
Virology; 2016 Sep; 496():147-165. PubMed ID: 27318152
[TBL] [Abstract][Full Text] [Related]
17. Human Antibody Responses to Emerging Mayaro Virus and Cocirculating Alphavirus Infections Examined by Using Structural Proteins from Nine New and Old World Lineages.
Smith JL; Pugh CL; Cisney ED; Keasey SL; Guevara C; Ampuero JS; Comach G; Gomez D; Ochoa-Diaz M; Hontz RD; Ulrich RG
mSphere; 2018; 3(2):. PubMed ID: 29577083
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.
Weger-Lucarelli J; Aliota MT; Wlodarchak N; Kamlangdee A; Swanson R; Osorio JE
J Virol; 2015 Dec; 90(5):2418-33. PubMed ID: 26676771
[TBL] [Abstract][Full Text] [Related]
19. Eilat virus host range restriction is present at multiple levels of the virus life cycle.
Nasar F; Gorchakov RV; Tesh RB; Weaver SC
J Virol; 2015 Jan; 89(2):1404-18. PubMed ID: 25392227
[TBL] [Abstract][Full Text] [Related]
20. A Quantitative Real-Time RT-PCR Assay for the Detection of
Vina-Rodriguez A; Eiden M; Keller M; Hinrichs W; Groschup MH
Biomed Res Int; 2016; 2016():8543204. PubMed ID: 28042576
[No Abstract] [Full Text] [Related]
[Next] [New Search]
